风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 从润本股份十大流通股东角度 责任编辑：小浪快报 11月20日，润本股份跌1.2%，截至发稿，报24.61元/股，成交5740.87万元，换手率2.25%，总市值99.57 亿元。润本股份股价已经连续5天下跌，区间累计跌幅5.16%。 国泰消费优选股票（005970）基金经理为李海。 资料显示，润本生物技术股份有限公司位于广东省广州市天河区珠江新城华夏路28号40楼，成立日期 2013年12月30日，上市日期2023年10月17日，公司主营业务涉及驱蚊类、个人护理类产品的研发、生产 和销售。主营业务收入构成为：婴童护理系列产品45.26%，驱蚊系列产品41.92%，精油系列产品 10.29%，其他产品2.47%，其他(补充)0.06%。 截至发稿，李海累计任职时间9年168天，现任基金资产总规模32.75亿元，任职期间最佳基金回报 139.47%， 任职期间最差基金回报-21.8%。 数据显示，国泰基金旗下1只基金位居润本股份 ...

Core Viewpoint - Runben Co., Ltd. has shown a mixed performance in terms of stock trading and financial results, with significant fluctuations in financing activities and a notable increase in shareholder numbers, indicating potential investor interest and market volatility [1][2]. Financing Activities - On October 30, Runben Co., Ltd. experienced a financing buy-in of 4.78 million yuan, while financing repayments amounted to 10.72 million yuan, resulting in a net financing outflow of 5.94 million yuan [1]. - The total financing balance reached 314 million yuan, accounting for 11.58% of the circulating market value, which is above the 80th percentile of the past year, indicating a high level of financing activity [1]. - In terms of securities lending, 300 shares were repaid, and 1,600 shares were sold short, with a total short sale value of 42,000 yuan, and the remaining short position stood at 9,100 shares, with a balance of 239,000 yuan, also above the 80th percentile of the past year [1]. Financial Performance - For the period from January to September 2025, Runben Co., Ltd. reported a revenue of 1.238 billion yuan, reflecting a year-on-year growth of 19.28%, while the net profit attributable to shareholders was 266 million yuan, showing a modest increase of 1.98% [2]. - The company has distributed a total of 316 million yuan in dividends since its A-share listing [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 26,200, a rise of 57.33%, while the average number of circulating shares per shareholder decreased by 36.44% to 3,948 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Guotai Consumption Preferred Stock and the entry of new shareholders such as Southern CSI 1000 ETF and ICBC Consumption Service Mixed A [3].

Core Viewpoint - In Q3 2025, the company achieved revenue of 342 million yuan, representing a growth of 16.67%, with stable overall growth. The revenue from mosquito repellent, baby care, and essential oil series was 132 million yuan (+48.5%), 146 million yuan (-2.8%), and 43 million yuan (-7.0%) respectively. The increase in mosquito repellent sales was mainly driven by the outbreak of Chikungunya fever, while the decline in baby care product sales was due to higher autumn and winter temperatures affecting the sales of baby cream [1][3][4]. Revenue and Profit Summary - For the first three quarters of 2025, the company reported a total revenue of 1.238 billion yuan, an increase of 19.28%, and a net profit attributable to the parent company of 266 million yuan, up by 1.98%. The basic EPS was 0.66 yuan (+3.13%), and the weighted ROE was 12.25%, down by 0.66 percentage points [2]. Product Performance - The Q3 revenue growth was primarily driven by mosquito repellent products, with online channels showing steady improvement. The GMV for the company's products on Tmall, JD, and Douyin platforms in Q3 was 130 million yuan (+19.5%), 74 million yuan (+23.8%), and 65 million yuan (+8.6%) respectively. Monthly GMV on Tmall showed fluctuations, with a year-on-year change of -9.7%, +48.8%, and +53.9% from July to September [3][4]. Marketing and Cost Analysis - The company's net profit in Q3 was 79 million yuan, down by 2.89%, with a non-recurring net profit of 74 million yuan, down by 7.58%. The decline in net profit was attributed to increased marketing expenditures due to intensified competition in the baby care market. The gross margin for Q3 was 58.96%, up by 1.39 percentage points, while the net margin was 22.93%, down by 4.62 percentage points. The sales, management, R&D, and financial expense ratios were 29.09% (+5.54 percentage points), 2.40% (-0.12 percentage points), 2.55% (-0.80 percentage points), and -0.80% (+2.40 percentage points) respectively [4]. Future Outlook - Looking ahead to Q4 2025, the company plans to focus on the youth care series and accelerate the launch of autumn and winter new products, while steadily expanding its multi-channel sales network. The company has introduced a new series of products targeting youth, including oil control and acne treatment products, and continues to focus on the baby care segment with key products like egg yolk oil cream [4]. Profit Forecast - Based on increased competition in the baby care market, the company has adjusted its profit forecast, expecting revenues of 1.58 billion, 1.90 billion, and 2.26 billion yuan for 2025-2027, with year-on-year growth rates of 19.7%, 20.3%, and 18.8% respectively. The net profits are projected to be 309 million, 374 million, and 449 million yuan, with corresponding P/E ratios of 37x, 30x, and 25x, maintaining a "buy" rating [5].

Investment Rating - The report maintains an "Accumulate" rating for the company [7] Core Insights - The company reported Q3 revenue of 342 million RMB, a year-on-year increase of 16.7%, while net profit attributable to shareholders was 79 million RMB, down 2.9% year-on-year, with a net profit margin of 22.9%, a decrease of 4.6 percentage points year-on-year [1][7] - The decline in profit margin is attributed to an increase in sales expense ratio and a decrease in interest income, although the overall profit margin remains resilient [1] - The company is expected to benefit from the peak season for infant and child products in Q4, with anticipated growth driven by products like egg yolk oil and lip balm [1] Revenue Breakdown - In Q3, the revenue from mosquito repellent, infant care, and essential oil series was 132 million, 146 million, and 43 million RMB respectively, with year-on-year growth rates of 48.5%, -2.8%, and -7.0% [2] - The average selling prices for these categories were 6.14, 8.51, and 8.87 RMB, reflecting year-on-year increases of 12.0%, 7.9%, and a decrease of 2.4% respectively [2] - The mosquito repellent series saw a significant increase in sales volume, driven by the chikungunya virus outbreak, while the infant care series experienced a price increase that partially offset a decline in sales volume [2] Channel Performance - Online channels showed impressive marginal growth, with Q3 GMV for Douyin, Taobao, and JD.com reaching 780.9 million, 1,295.7 million, and 725.1 million RMB, representing year-on-year growth of 30.6%, 20.6%, and 21.9% respectively [3] - The launch of new products in the youth and children’s series is expected to tap into niche market demands, potentially driving long-term growth [3] Cost Structure - Q3 gross margin was 59.0%, up 1.4 percentage points year-on-year, while the sales expense ratio increased to 29.1%, up 5.4 percentage points year-on-year [4] - The increase in sales expenses is primarily due to heightened online market investments, while management and R&D expense ratios saw slight decreases [4] Profit Forecast and Valuation - The company’s net profit forecasts for 2025-2027 have been adjusted to 311 million, 387 million, and 465 million RMB, reflecting decreases of 4.9%, 5.8%, and 8.7% from previous estimates [5] - Based on comparable companies, a target price of 32.54 RMB is set for 2026, corresponding to a PE ratio of 34x, with the rating maintained at "Accumulate" [5]

Core Insights - Runben Co., Ltd. experienced a stock price increase of 2.84% on September 23, with a trading volume of 199 million yuan [1] - The company reported a financing net purchase of 19.41 million yuan on the same day, indicating strong investor interest [1][2] - As of June 30, 2025, Runben's revenue reached 895 million yuan, reflecting a year-on-year growth of 20.31% [2] Financing and Margin Trading - On September 23, Runben's financing buy amounted to 40.59 million yuan, with a total financing balance of 333 million yuan, representing 10.97% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of leverage [1] - The company also reported a margin trading situation with a short selling amount of 2.94 million yuan and a remaining short selling balance of 249,500 yuan [1] Shareholder and Institutional Holdings - As of June 30, 2025, the number of shareholders increased by 60.52% to 16,600, while the average number of circulating shares per person decreased by 37.70% to 6,211 shares [2] - Runben has distributed a total of 316 million yuan in dividends since its A-share listing [3] - New institutional shareholders include Hong Kong Central Clearing Limited and Guotai Consumer Preferred Stock, among others, indicating growing institutional interest [3]

Group 1 - The core viewpoint of the article is that Minsheng Securities has given a "recommended" rating to Runben Co., Ltd. (603193.SH) based on its strong performance and growth potential [2] - Runben Co., Ltd. released its semi-annual report for 2025, indicating a solid financial performance [2] - The baby and child care product series continues to experience high growth, with an increasingly comprehensive product matrix [2] - The gross profit margin remains stable, with a net profit margin attributable to the parent company of 20.95% for the first half of 2025 [2] - The company is continuously consolidating its online competitive advantage while actively expanding offline channels, with Sam's Club contributing incremental growth [2]

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [4][5]. Core Insights - The company achieved a revenue of 895 million yuan in H1 2025, representing a year-on-year growth of 20.31%. The net profit attributable to shareholders was 188 million yuan, up 4.16% year-on-year [1]. - The baby and child care segment continues to show strong growth, with revenue reaching 405 million yuan, a year-on-year increase of 38.73%. The product matrix has been enhanced with over 40 new or upgraded products launched in H1 2025 [2]. - The company is expanding its target audience from infants to teenagers, introducing products such as acne treatment and skincare for adolescents, which reflects its strategy to meet unmet consumer needs [2]. Financial Performance - The gross profit margin for H1 2025 was 58.01%, a slight decrease of 0.63 percentage points year-on-year. The net profit margin for the same period was 20.95%, down 3.25 percentage points year-on-year [3]. - The company’s sales, management, and R&D expense ratios for H1 2025 were 30.25%, 1.81%, and 1.83%, respectively, indicating a slight increase in sales expenses compared to the previous year [3]. - The forecast for net profit attributable to shareholders for 2025-2027 is projected to be 335 million, 434 million, and 552 million yuan, with respective year-on-year growth rates of 11.6%, 29.7%, and 27.0% [4][5]. Market Position and Strategy - The company is solidifying its online market position while actively expanding its offline channels, with significant contributions from new partnerships, such as with Sam's Club [4]. - The report highlights the company's leadership in the baby mosquito repellent market and its proactive approach in the baby care sector, which is expected to unlock further growth potential [4].

Investment Rating - The report maintains an "Accumulate" rating for the company [7] Core Views - The company reported a revenue of 895 million RMB for H1 2025, representing a year-on-year increase of 20.3%, with a net profit attributable to the parent company of 188 million RMB, up 4.2% year-on-year. The revenue growth for Q1 and Q2 of 2025 was 44.0% and 13.5% respectively, while the net profit showed a year-on-year increase of 24.6% in Q1 but a slight decline of 0.8% in Q2. The slower growth in Q2 is attributed to last year's high base during the mosquito repellent season and new product launches. However, with the introduction of new products targeting teenagers, the company is expected to accelerate growth in H2 2025 [1][5][7] Summary by Sections Revenue and Profitability - In H1 2025, the mosquito repellent product line generated 375 million RMB in revenue, a year-on-year increase of 13.4%, with a gross margin of 53.7%. The baby care product line achieved 405 million RMB in revenue, up 38.7% year-on-year, with a gross margin of 61.1%. The growth in the baby care segment is primarily due to the expansion of the target audience to include teenagers and the launch of oil-control and acne treatment products. The essential oil product line saw a revenue decline of 14.6% year-on-year, with a gross margin of 61.8% [2] Cost Structure - The gross margin for H1 2025 was 58.0%, a decrease of 0.6 percentage points year-on-year, likely due to increased discounting during the 618 shopping festival. The sales expense ratio increased to 30.25%, up 1.5 percentage points year-on-year. The financial expense ratio saw significant changes due to a decrease in interest income [3] Product and Channel Development - The company actively expanded its offline channels in H1 2025, including a new partnership with Sam's Club. The company launched or upgraded over 40 products, including children's sunscreen gel and a new series targeting teenagers. The introduction of these new products is expected to drive performance growth in H2 2025 [4] Earnings Forecast and Valuation - The revenue estimates for 2025-2027 have been adjusted downwards to 1.614 billion RMB, 2.054 billion RMB, and 2.577 billion RMB respectively, reflecting a decrease of 7.7%, 9.0%, and 10.3% from previous estimates. The net profit estimates for the same period have also been revised down to 327 million RMB, 411 million RMB, and 510 million RMB, representing decreases of 19.5%, 18.6%, and 18.3% respectively. The target price is set at 37.74 RMB, corresponding to a 37 times PE for 2026 [5]

Investment Rating - The investment rating for the company is "Buy" with an expectation of over 10% return relative to the CSI 300 index in the next six months [11]. Core Views - The company is positioned as a leader in the life care sector, focusing on mosquito repellent and baby care products, with a diversified product line enhancing market competitiveness [5]. - The company achieved a revenue of 1.318 billion yuan in 2024, representing a year-on-year growth of 27.61%, and a net profit of 300 million yuan, up 32.80% year-on-year [5][7]. - The online sales channel has shown significant growth, particularly on platforms like Douyin, contributing to the overall revenue increase [5][7]. - The company is expected to maintain steady growth due to product innovation and channel optimization, with projected net profits of 372 million yuan, 481 million yuan, and 615 million yuan for 2025, 2026, and 2027 respectively [7][9]. Summary by Sections Company Overview - Founded in 2006, the company aims to become a global leader in life and personal care products, offering a range of items including mosquito repellent and baby care products [5]. - The company has established a broad sales network both domestically and internationally, with a strong online presence [5]. Financial Performance - In 2024, the company reported a revenue of 1.318 billion yuan, a 27.61% increase from the previous year, and a net profit of 300 million yuan, reflecting a 32.80% growth [5][9]. - The quarterly revenue breakdown for 2024 shows significant growth, particularly in Q2 and Q4, with Q4 net profit experiencing some fluctuations due to increased promotional expenses [5][7]. Product Performance - The mosquito repellent product line generated 439 million yuan in revenue in 2024, a 35.39% increase, with a gross margin improvement to 54.18% [7]. - The baby care product line achieved 690 million yuan in revenue, up 32.42%, with a gross margin of 59.81% [7]. Channel Strategy - The online sales channel contributed 970 million yuan in revenue, a 23.80% increase, while non-platform distribution revenue reached 347 million yuan, growing by 39.64% [7]. - The company is enhancing its collaboration with e-commerce platforms to optimize its market presence and improve gross margins [7]. Future Projections - The company forecasts continued revenue growth, with expected revenues of 1.710 billion yuan, 2.131 billion yuan, and 2.530 billion yuan for 2025, 2026, and 2027 respectively [9]. - The projected net profit for the next three years indicates a robust growth trajectory, with EPS expected to rise from 0.92 yuan in 2025 to 1.52 yuan in 2027 [9].

润本生物技术股份有限公司 首次公开发行股票并在主板上市 招股意向书附录 目录 | 序号 | 文件名 | 页码 | | --- | --- | --- | | 1 | 发行保荐书 | 1 | | 2 | 财务报表及审计报告 | 28 | | 3 | 审阅报告 | 173 | | 4 | 内部控制鉴证报告 | 276 | | 5 | 经注册会计师核验的非经常性损益明细表 | 295 | | 6 | 法律意见书 | 306 | | 7 | 律师工作报告 | 495 | | 8 | 公司章程（草案） | 657 | | 9 | 中国证监会同意发行人本次公开发行注册的文件 | 722 | 申万宏源证券承销保荐有限责任公司 关于润本生物技术股份有限公司 首次公开发行股票并在主板上市之 发行保荐书 保荐机构 二〇二三年六月 1 | 目录 2 | | --- | | 第一节 本次证券发行基本情况 4 | | 一、本次具体负责推荐的保荐代表人 4 | | 二、本次证券发行项目协办人及其他项目组成员 4 | | 三、发行人情况 5 | | 四、保荐机构及其关联方与发行人及其关联方之间的利害关系及主要业务往来 | | 情况说明 5 ...